MFTZ-1 reduces constitutive and inducible HIF-1α accumulation and VEGF secretion independent of its topoisomerase II inhibition

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 9, 2010, Pages 2281-2291

  Dai, Mei ^a   Miao, Ze Hong ^a   Ren, Xuan ^a   Tong, Lin Jiang ^a   Yang, Na ^a   Li, Ting ^a   Lin, Li Ping ^a   Shen, Yue Mao ^b   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

Angiogenesis; HIF 1 ; MFTZ 1; Topoisomerase II inhibitor; VEGF

Indexed keywords

14 ETHYL 2,5,11 TRIMETHYL 4,13,19,20 TETRAOXA TRICYCLO(14.2.1.1(7,10))EICOSANE 3,12 DIONE; 14-ETHYL-2,5,11-TRIMETHYL-4,13,19,20-TETRAOXA-TRICYCLO(14.2.1.1(7,10))EICOSANE-3,12-DIONE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ICOSANOID; MACROLIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; VASCULOTROPIN A;

ANIMAL; ARTICLE; DRUG EFFECT; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN PROCESSING; RAT; SECRETION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; EICOSANOIDS; ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MACROLIDES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOPOISOMERASE II INHIBITORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 78649386068     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00822.x     Document Type: Article

References (42)

1. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003; 2: 803-11.
2. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today. 2007; 12: 853-9.
3. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006; 70: 1469-80.
4. Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp. 2006; 272: 15-25; discussion 25-36.
5. Fukuda R, Hirota K, Fan F, et al. Insulinlike growth factor 1 induces hypoxiainducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002; 277: 38205-11.
6. Slomiany MG, Black LA, Kibbey MM, et al. IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2006; 342: 851-8.
7. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002; 277: 27975-81.
8. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens. 1996; 5: 35-44.
9. Mamane Y, Petroulakis E, LeBacquer O, et al. mTOR, translation initiation and cancer. Oncogene. 2006; 25: 6416-22.
10. Trisciuoglio D, Iervolino A, Zupi G, et al. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell. 2005; 16: 4153-62.
11. Segrelles C, Ruiz S, Santos M, et al. Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis. 2004; 25: 1137-47.
12. Tong Y, Zhang X, Tian F, et al. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int J Cancer. 2005; 114: 843-53.
13. Xie CY, Zhu H, Lin LP, et al. MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison. Mol Cancer Ther. 2007; 6: 3059-70.
14. Zhao PJ, Fan LM, Li GH, et al. Antibacterial and antitumor macrolides from Streptomyces sp. Is9131. Arch Pharm Res. 2005; 28: 1228-32.
15. Li MH, Miao ZH, Tan WF, et al. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res. 2004; 10: 8266-74.
16. Blancher C, Moore JW, Talks KL, et al. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000; 60: 7106-13.
17. Zhou J, Schmid T, Frank R, Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem. 2004; 279: 13506-13.
18. Ben-Shoshan M, Amir S, Dang DT, et al. 1{alpha},25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007; 6: 1433-9.
19. Qin Y, Meng L, Hu C, et al. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther. 2007; 6: 2429-40.
20. Sowter HM, Raval RR, Moore JW, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003; 63: 6130-4.
21. Ashton AW, Yokota R, John G, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem. 1999; 274: 35562-70.
22. Calvani M, Rapisarda A, Uranchimeg B, et al. Hypoxic induction of an HIF-1alphadependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood. 2006; 107: 2705-12.
23. Zhong L, Guo XN, Zhang XH, et al. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta. Cancer Biol Ther. 2006; 5: 323-30.
24. Zhao H, Liu H, Chen Y, et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006; 66: 8779-87.
25. Jiang BH, Jiang G, Zheng JZ, et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001; 12: 363-9.
26. Kong X, Alvarez-Castelao B, Lin Z, et al. Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J Biol Chem. 2007; 282: 15498-505.
27. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001; 21: 3995-4004.
28. Pore N, Jiang Z, Shu HK, et al. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res. 2006; 4: 471-9.
29. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res. 2006; 4: 601-5.
30. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature. 2006; 441: 457-62.
31. Guo XN, Zhong L, Zhang XH, et al. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim Biophys Acta. 2004; 1673: 186-93.
32. Kamiyama H, Takano S, Tsuboi K, et al. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol. 2005; 131: 205-13.
33. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004; 6: 485-95.
34. Zhu H, Huang M, Yang F, et al. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther. 2007; 6: 484-95.
35. Harker WG, Slade DL, Parr RL, et al. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995; 55: 1707-16.
36. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007; 26: 281-90.
37. Wada-Kiyama Y, Kiyama R. Periodicity of DNA bend sites in human epsilon-globin gene region. Possibility of sequence-directed nucleosome phasing. J Biol Chem. 1994; 269: 22238-44.
38. Yang SX, Hewitt SM, Steinberg SM, et al. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep. 2007; 17: 281-7.
39. Dong K, Wang R, Wang X, et al. Tumorspecific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat. 2009; 113: 443-56.
40. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-32.
41. Duyndam MC, van Berkel MP, Dorsman JC, et al. Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate hypoxia-inducible factor I activity in human ovarian cancer cells. Biochem Pharmacol. 2007; 74: 191-201.
42. nd, Stephen AG, et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res. 2007; 13: 1010-8.